DISPOSITIFS Nasal et pulmonaire RECHERCHE - RESEARCH NEMERA AU PLUS PRÈS DE LA SCIENCE NEMERA IS GETTING CLOSER TO SCIENCE La société Nemera et le Centre d’Etude des respiration. Les nanoparticules sont de très petiteTests are ongoing and Nemera is working on a Pathologies Respiratoires (CEPR) de l’Université taille, presque un million de fois plus petites qu’unsuitable device. On the other hand, the company François Rabelais de Tours ont constitué un grain de sable – et trop petites pour être vues avecis also a member of the CUPIDO project (Cardio partenariat visant à améliorer l’efficacité des un microscope conventionnel. L’exploitation d’un Ultraefficient nanoParticles for Inhalation traitements des médicaments dans la cavité tel système comme voie d’administration pourrait of Drug PrOducts) funded by the European nasale en développant une nouvelle méthode révolutionner le domaine cardiovasculaire, en Union. “It proposes an innovative solution: the d’administration nasale. Les chercheurs travaillentdevenant la première approche thérapeutique non translation of nanomedical applications toward sur une nouvelle méthode de délivrance pour invasive à cibler spécifiquement le cœur. Nemeraathe cardiac field. The goal is to tackle the obtenir un meilleur dépôt du médicament dans pour mission de développer l’inhalateur » souligne,origin of cardiovascular diseases by developing les différentes régions anatomiques cibles des Raphaële Audibert, responsable des catégories inhalable nanoparticles that can deliver a therapy cavités nasales. Des tests sont en cours et NemeraInhalation & Dermal. directly to the heart as simply as breathing. The travaille sur un dispositif adapté. D’autre part, la nanoparticles are very small, almost a million société est aussi membre du projet CUPIDO (CardioNemera and the Research Centre for Respiratory times smaller than a grain of sand - and too Ultraefficient nanoParticles for Inhalation of DrugDiseases (CEPR) of the François Rabelais small to be seen with a conventional microscope. prOducts), financé par l’Union européenne. « Il University of Tours have entered a partnership The exploitation of such a system as a delivery propose une solution innovante : l’application desaimed at improving the efficiency of drug route could revolutionize the cardiovascular area, nanotechnologies au domaine cardiovasculaire. delivery through the nasal cavity by developing by becoming the first non-invasive therapeutic Le but est de s’attaquer à l’origine des a new nasal delivery method. The researchers approach that specifically targets the heart. maladies cardiovasculaires en développant des are working on a new delivery method to Nemera’s mission is todevelop the inhaler,” nanoparticules inhalables qui puissent délivrer lesobtain a better deposition of the drug in varioussays Raphaële Audibert, Inhalation & Dermal médicaments directement au cœur par une simple anatomical target areas of the nasal cavities. Categories Director. From the nose antibodies for crossing route in particular, but pump especially dedicated to the brain the blood-brain barrier. it is also possible to use to these formulas. But 56 And the manufacturers are conventional pumps,” adds preservative-free systems The “nose-to-brain” preparing as well. “We Thomas Grinnan, Senior are not just for nasal passage is also being have developed specific Commercial Director, delivery. We are currently literally explored for systems for liquid and Healthcare, EMEA, at developing a pump for treatments of the central powder formulations Silgan. another application,” nervous system within for the ‘nose-to-brain’ Thomas Grinnan says disorders such as route: they are different while refraining from Alzheimer’s or Parkinson’s. from conventional nasal Preservative-free has telling us more. Almost Nose-to-brain drug delivery systems and allow now become a classic all the suppliers currently delivery is subject to delivering an important have a “preservative-free” increased interest and part of the dose through “Customers want to be offer. Just like Nemera, research. Major challenges the olfactory area,” Hervé able to choose systems which has developed a are yet to be taken up - Pacaud says. “We’ve that are suitable for their preservative-free version crossing the blood-brain noticed a rising interest for preservative-free formulas. of its Advancia® platform, barrier, targeting the this route as the patient For example, it is known called AdvanciaPF.® specific deposition areas can administer himself his that BKC (benzalkonium In addition, Ursatec is - but the potential is treatment, which acts more chloride - a preservative launching a novelty this there. There are ongoing rapidly than injections - used in the drops for the year: the SoftBreezer®, a clinical research studies between 5 to 20 minutes nose or eyes, Editor’s preservative-free pocket-size focused on oxytocin against 45 minutes to note) may have adverse nebulizer device (available delivery in patients one hour in the case of effects on the nose if used in 5 and 10 ml) for aqueous suffering from autism or injections. Certain pumps for a long term. At Silgan, solutions. It is suitable the potential use of shark on the market target this we designed the PFPN for so-called “preventive” Avril / Mai / Juin - 2018Doses 71 /Le Magazine du Packaging des Produits de Santé